MeSH term
Frequency | Condition_Probility | Adult | 20 | 0.0 |
Female | 35 | 0.0 |
Humans | 87 | 0.0 |
Male | 37 | 0.0 |
Middle Aged | 17 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 19 | 0.0 |
Risk Factors | 4 | 0.0 |
Sex Factors | 3 | 0.0 |
Binding Sites/physiology | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 6 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Kinetics | 10 | 0.0 |
Models, Molecular | 2 | 0.0 |
Plasminogen/*metabolism | 14 | 36.0 |
Protein Binding/physiology | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 40 | 0.0 |
Streptokinase/*metabolism | 2 | 66.0 |
Surface Plasmon Resonance | 2 | 1.0 |
Animals | 20 | 0.0 |
Binding Sites | 4 | 0.0 |
Cells, Cultured | 6 | 0.0 |
Fibrinolysis | 5 | 3.0 |
Peptide Fragments/metabolism | 3 | 0.0 |
Plasminogen/metabolism | 5 | 12.0 |
Protein Binding | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Cell Membrane/metabolism | 3 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Immunohistochemistry | 2 | 0.0 |
Rats | 2 | 0.0 |
Child | 7 | 0.0 |
Gene Frequency | 14 | 0.0 |
Paternity | 2 | 2.0 |
Phenotype | 13 | 0.0 |
Plasminogen/*genetics | 12 | 66.0 |
*Polymorphism, Genetic | 11 | 0.0 |
Blotting, Western | 2 | 0.0 |
Mice | 12 | 0.0 |
Plasmin/metabolism | 5 | 5.0 |
Serine Proteinase Inhibitors/pharmacology | 2 | 4.0 |
Amino Acid Sequence | 5 | 0.0 |
Comparative Study | 11 | 0.0 |
Molecular Sequence Data | 10 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Age Factors | 2 | 0.0 |
Prevalence | 2 | 0.0 |
Gene Targeting | 2 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Transfection | 2 | 0.0 |
Exons/genetics | 2 | 0.0 |
Pedigree | 8 | 0.0 |
Plasminogen/deficiency/*genetics | 2 | 100.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Microspheres | 2 | 1.0 |
Binding, Competitive | 2 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
Adolescent | 7 | 0.0 |
Plasminogen/*deficiency | 3 | 75.0 |
Aged | 8 | 0.0 |
Molecular Weight | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Fibrinolysis/*physiology | 2 | 2.0 |
Plasminogen Activators/*metabolism | 5 | 22.0 |
Tissue Plasminogen Activator/*metabolism | 3 | 15.0 |
Isoelectric Focusing | 8 | 1.0 |
Plasminogen/*analysis | 5 | 55.0 |
In Vitro | 2 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Immunoblotting | 3 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Cell Line | 4 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
Family Health | 2 | 0.0 |
Homozygote | 2 | 0.0 |
Base Sequence | 7 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Europe | 2 | 0.0 |
English Abstract | 6 | 0.0 |
Mutation | 2 | 0.0 |
Plasminogen/*deficiency/*genetics | 3 | 100.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Blood Proteins/genetics | 2 | 3.0 |
*Genetics, Population | 4 | 1.0 |
Polymorphism, Genetic | 4 | 0.0 |
Alleles | 7 | 0.0 |
Blood Proteins/*genetics | 5 | 3.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
Genetic Markers/genetics | 2 | 0.0 |
Japan | 4 | 0.0 |
Asian Continental Ancestry Group/*genetics | 3 | 0.0 |
China | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Time Factors | 3 | 0.0 |
Blood Group Antigens/*genetics | 2 | 1.0 |
Gene Frequency/genetics | 2 | 0.0 |
Genetic Markers | 5 | 0.0 |
Lod Score | 2 | 0.0 |
Plasminogen/*genetics/isolation & purification | 2 | 100.0 |
Variation (Genetics) | 2 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Fibrinolysis/*drug effects | 2 | 3.0 |
Receptors, Cell Surface/metabolism | 3 | 0.0 |
Urinary Plasminogen Activator/metabolism | 3 | 6.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 2 | 0.0 |
Reference Values | 6 | 0.0 |
Polymorphism, Genetic/*genetics | 3 | 0.0 |
Transferrin/genetics | 2 | 4.0 |
*Intracellular Signaling Peptides and Proteins | 2 | 0.0 |
*Microtubule-Associated Proteins | 2 | 2.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
Chromosome Deletion | 2 | 0.0 |
Genotype | 2 | 0.0 |
Urinary Plasminogen Activator/*metabolism | 3 | 8.0 |
Blood Coagulation Tests | 2 | 1.0 |
Hepatitis, Viral, Human/*blood | 2 | 20.0 |
Liver Cirrhosis/blood | 2 | 4.0 |
Pregnancy | 3 | 0.0 |
Antithrombin III/*analysis | 2 | 2.0 |
Korea | 2 | 0.0 |
Mice, Inbred C57BL | 3 | 0.0 |
Glycoproteins/*metabolism | 2 | 1.0 |
Thrombospondins | 2 | 1.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
MSH Release-Inhibiting Hormone/*pharmacology | 2 | 66.0 |
*Fibrinolysis | 2 | 1.0 |
Disease Models, Animal | 2 | 0.0 |
